// App-Quantinova.ai

: PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).

Researchers

Presenter

  • Maha Hussain

Principal Investigators

  • Karim Fizazi

  • Fred Saad

  • Per Rathenborg

  • Neal D. Shore

  • Eren Demirhan

  • Katharina Modelska

  • De Phung

  • Andrew Krivoshik

  • Cora N. Sternberg

Medical Centers

  • Northwestern University, Chicago, IL

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Herlev Hospital, Herlev, Denmark

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Amgen Inc, South San Francisco, CA

  • Amgen Inc, South San Francisco, CA

  • Astellas Pharma Europe, Leiden, Netherlands

  • Astellas Pharma, Inc., Northbrook, IL

  • San Camillo-Forlanini Hospital, Rome, Italy

Locations

  • United States

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • NCT02003924

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved